ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

Katherine L Pogue-Geile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.